Jolly Pharma has backed a funding round for cancer immunotherapy developer Carsgen Therapeutics through its Jolly Innovation Ventures unit.
China-based cancer treatment developer Carsgen Therapeutics has closed a $30m series B round co-led by Jolly Innovation Ventures, the investment vehicle of pharmaceutical firm Jolly Pharma.
Venture capital firm KTB Ventures co-led the round, which also featured participation by Kaitai Capital and JIC GenesisFountain Healthcare Ventures. Chi Hoon Hyun, investment director at KTB, will join Carsgen’s board of directors,
Carsgen is working on immunotherapies for forms of liver, lung and brain cancer including glioblastoma, the most severe form of brain…